Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iBio, Inc. (NASDAQ: IBIO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q and 8‑K, as they appear on the EDGAR system. iBio is a preclinical-stage biotechnology company that uses AI and advanced computational biology to develop precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases, and its filings offer detailed insight into this strategy.
Through annual and quarterly reports, investors can review iBio’s description of its AI Drug Discovery Platform, preclinical pipeline programs such as IBIO‑610 and IBIO‑600, risk factors, liquidity and capital resources. Current reports on Form 8‑K capture material events, including financing transactions, Nasdaq listing compliance updates, new preclinical data disclosures, changes to corporate presentations and the results of annual stockholder meetings. The company’s definitive proxy statements (DEF 14A) provide information on board structure, executive compensation and governance matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as preclinical data updates, capital-raising terms, and changes in risk disclosures. Real-time updates ensure that new IBIO filings, including Form 4 insider transaction reports when available, appear promptly in the feed.
By using this IBIO filings page, investors and researchers can efficiently navigate iBio’s regulatory history, from its business description and pipeline details to financing structures and governance decisions, while AI-generated overviews make complex SEC documents more accessible.
Affinity Asset Advisors, LLC and Michael Cho report a 9.99% beneficial stake in iBio, Inc. common stock. They collectively report control over 2,401,616 shares, including 144,416 shares issuable upon exercise of warrants.
The securities are held through Affinity Healthcare Fund, LP, for which Affinity Asset Advisors acts as investment manager. The warrants are subject to a 9.99% beneficial ownership limitation, and the position is certified as being held in the ordinary course of business, not to influence control of iBio.
iBio, Inc. received a Schedule 13G filing from several Millennium-affiliated investment entities and Israel A. Englander disclosing a new passive ownership position. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,234,295 shares of iBio common stock, while Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report 1,235,827 shares, representing 5.2% of the outstanding common stock in each case.
The ownership percentage is based on 23,895,789 iBio shares outstanding, combining 22,487,308 shares reported in a prior Form 10‑Q/A and 1,408,481 shares issued in a recent private placement. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of iBio, and they entered into a joint filing agreement to report this position together.
iBio, Inc. entered into a securities purchase agreement with institutional investors for a private placement priced at-the-market, raising approximately $26 million in gross proceeds. The company agreed to sell 1,408,481 shares of common stock at $2.35 per share and issue pre-funded warrants to purchase up to 9,653,257 additional shares at an exercise price of $0.001 per share, with a purchase price of $2.349 per pre-funded warrant.
The closing is expected on or about January 13, 2026, and iBio plans to use the net proceeds to advance its preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and myostatin/activin A bispecific programs, as well as other preclinical assets, and for working capital and general corporate purposes. The company granted investors registration rights for resale of the shares and warrant shares and agreed to temporary restrictions on additional equity issuances and certain corporate actions until the resale registration statement becomes effective or 60 days after closing.
iBio, Inc. reported a stock option grant to a director on a Form 4. On 11/20/2025, the director received 13,500 stock options with an exercise price of $1 per share, expiring on 11/19/2035. These options vest pro rata on a monthly basis over twelve months starting on the grant date. Following this transaction, the director beneficially owns 13,500 derivative securities, held as a direct ownership position.
iBio, Inc. (IBIO) reported a routine insider equity grant on a Form 4. A company director received a stock option (right to buy) covering 13,500 shares of common stock on 11/20/2025 with an exercise price of $1 per share. The option expires on 11/19/2035, giving a long window to purchase shares at that price. These options vest on a pro rata monthly basis over twelve months starting from the grant date, meaning the director earns the right to exercise a portion of the option each month during the first year.
iBio, Inc. (IBIO) reported a director equity award on a Form 4. On 11/20/2025, the reporting person received a stock option grant covering 13,500 shares of iBio common stock. The options have an exercise price of $1 per share and an expiration date of 11/19/2035.
The filing states that these options vest on a pro rata basis each month over twelve months, starting on the grant date. Following this grant, the reporting person beneficially owns 13,500 derivative securities directly in the form of these options.
iBio, Inc. (IBIO) disclosed that a director received a new stock option grant reported on Form 4. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1 per share. These options vest on a pro rata monthly basis over twelve months starting from the grant date, aligning the director’s compensation with the company’s share performance over the coming year. The options have an expiration date of 11/19/2035 and are held as direct ownership by the reporting person.
iBio, Inc. (IBIO) reported that one of its directors received a new stock option grant. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share.
These options vest pro rata on a monthly basis over twelve months starting from the grant date, meaning the director earns a portion of the options each month during the first year. The options have an expiration date of 11/19/2035, giving a long period in which they may be exercised, subject to the vesting schedule and any applicable company or regulatory requirements.
iBio, Inc. reported a stock-based compensation grant to one of its directors. On 11/20/2025, the director received a stock option to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share. The option becomes exercisable gradually, vesting in equal monthly installments over twelve months starting on the grant date, and expires on 11/19/2035 if not exercised. The filing indicates the director holds these options directly.
iBio, Inc. reported the results of its Annual Meeting of Stockholders held on November 20, 2025. Stockholders representing 10,566,364 shares were present in person or by proxy, constituting a quorum. Two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, were elected to three-year terms expiring at the 2028 Annual Meeting.
Stockholders ratified the appointment of Grassi & Co., CPAs, P.C. as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 9,912,837 votes for and 594,576 against. They also approved, on an advisory basis, the executive compensation program, with 4,392,583 votes for and 403,278 against.
In addition, stockholders approved holding future advisory votes on executive compensation every year, with 4,290,210 votes favoring a one-year frequency. Consistent with this vote and the Board’s recommendation, the Company will conduct an annual advisory say-on-pay vote until the next required vote on frequency.